14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VREX vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Varex Imaging Corporation (VREX) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VREX carries a Unified Composite Score of 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).
Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 8.3% operating margin) and revenue trajectory (+70.7% vs. +3.7% YoY).
Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VREX vs DCTH. Trailing 12-month operating profitability (VREX 8.3% vs DCTH 5.2%) and valuation multiples (VREX 16.9x vs DCTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment82.4% of Rev ($91M)
90D Engineering Disclosures0 Published
Investor FAQ VREX vs DCTH Key Questions & Quantitative Answers
As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Varex Imaging Corporation (VREX) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VREX carries a Unified Composite Score of 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 8.3% operating margin) and revenue trajectory (+70.7% vs. +3.7% YoY). Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: VREX posts +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). On trailing 12-month operating scale, VREX generates $865M in USD-normalized revenue versus $110M for DCTH. In operating R&D and SG&A reinvestment, VREX deploys 26.0% of Rev ($225M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
VREX screens cheaper on headline valuation multiples. VREX trades at 16.9x Forward P/E, 34.3x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VREX (4.6% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 5% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.